@prefix fibo-fnd-rel-rel: <http://www.omg.org/spec/EDMC-FIBO/FND/Relations/Relations/> .
@prefix owl:   <http://www.w3.org/2002/07/owl#> .
@prefix owl2: <http://www.w3.org/2006/12/owl2#> .
@prefix xsd:   <http://www.w3.org/2001/XMLSchema#> .
@prefix fibo-fnd-dt-fd: <http://www.omg.org/spec/EDMC-FIBO/FND/DatesAndTimes/FinancialDates/> .
@prefix skos:  <http://www.w3.org/2004/02/skos/core#> .
@prefix rdfs:  <http://www.w3.org/2000/01/rdf-schema#> .
@prefix fibo-fnd-arr-arr: <http://www.omg.org/spec/EDMC-FIBO/FND/Arrangements/Arrangements/> .
@prefix chear: <http://hadatac.org/ont/chear#> .
@prefix fibo-fnd-aap-agt: <http://www.omg.org/spec/EDMC-FIBO/FND/AgentsAndPeople/Agents/> .
@prefix dct:   <http://purl.org/dc/terms/> .
@prefix rdf:   <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix fibo-fnd-arr-id: <http://www.omg.org/spec/EDMC-FIBO/FND/Arrangements/IdentifiersAndIndices/> .
@prefix sio-f: <http://semanticscience.org/ontology/sio.owl#> .
@prefix sio:   <http://semanticscience.org/resource/> .
@prefix fibo-fnd-utl-av: <http://www.omg.org/spec/EDMC-FIBO/FND/Utilities/AnnotationVocabulary/> .
@prefix sm:    <http://www.omg.org/techprocess/ab/SpecificationMetadata/> .
@prefix fibo-fnd-arr-cls: <http://www.omg.org/spec/EDMC-FIBO/FND/Arrangements/ClassificationSchemes/> .
@prefix sco-i: <https://tw.rpi.edu/Courses/Ontologies/2018/DiabetesTreatmentSupport/DiabetesTreatmentSupport_Individuals/> .
@prefix sco: <https://idea.tw.rpi.edu/projects/heals/studycohort/> .
@prefix sco-i: <https://idea.tw.rpi.edu/projects/heals/studycohort_individuals/> .
@prefix obo: <http://purl.obolibrary.org/obo/> .
@prefix ncit: <http://purl.obolibrary.org/obo/NCIT_> .

sco-i:RamiprilArm
       a    owl:Class, sco:InterventionArm; 
       rdfs:subClassOf        sio:StudySubject;
       sio:isParticipantIn    sco-i:TelmisartanRamiprilStudy;   
       sio:hasAttribute    
       [ a sco:PopulationSize; sio:hasValue 8576],
       [ a sio:Age; sio:hasUnit sio:Year;
          sio:hasAttribute
          [ a sio:Mean; sio:hasValue 66.4],
          [a sio:StandardDeviation; sio:hasValue 7.2 ]  
        ] . 

sco-i:TelmisartanRamiprilStudy
	a  owl:NamedIndividual , ncit:C71104 ;
	rdfs:seeAlso  "https://ClinicalTrials.gov/NCT00153101" ;
	dct:abstract "In patients who have vascular disease or high-risk diabetes without heart failure, angiotensin-converting-enzyme (ACE) inhibitors reduce mortality and morbidity from cardiovascular causes, but the role of angiotensin-receptor blockers (ARBs) in such patients is unknown. We compared the ACE inhibitor ramipril, the ARB telmisartan, and the combination of the two drugs in patients with vascular disease or high-risk diabetes.";
	dct:creator     "ONTARGET Investigators", "Yusuf S.", "Teo KK.", "Pogue J.", "Dyal L.", "Copland I.", "Schumacher H.", 
"Dagenais G.", "Sleight P.", "Anderson C." ;
	dct:title       "Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events" ;
	sm:documentURL  
	"https://care.diabetesjournals.org/lookup/external-ref?access_num=10.1056/NEJMoa0801317&link_type=DOI" ;
	sio:hasParticipant   sco-i:RamiprilArm .
